IL4 and asthma: Dupilumab attenuated the expression of both TSLP and IL-8 induced by co-stimulation with dsRNA and IL-4/IL-13 in HSAECs (Fig 6), suggesting its potential therapeutic benefit in virus-induced asthma exacerbations, particularly in type 2 asthma.